Armata Pharmaceuticals Logo
US04216R1023
A2PKLC
ARMP

Armata Pharmaceuticals

Prognoza

Średnia cena docelowa analityków wynosi 13,67 € (+395,29%). Mediana wynosi 13,67 € (+395,29%).

Kupuj
  4
Trzymaj
  0
Sprzedaj
  0

Dyskusje w społeczności

Nie ma jeszcze dyskusji o tym aktywie.

Rozpocznij dyskusję

  • Armata Pharmaceuticals rises after FDA decision naming AP-SA02 a "Breakthrough Therapy"

    Armata Pharmaceuticals’ stock rose sharply after the FDA granted the phage candidate AP-SA02 "Breakthrough Therapy" status for the adjuvant treatment of complicated Staphylococcus aureus bacteremia. The designation is based on phase 1b/2a data in which 100% of patients treated with AP-SA02 showed a sustained clinical response 28 days after end of therapy versus 75% in the placebo group. AP-SA02 also received Fast Track and Qualified Infectious Disease Product designations; the treatment was well tolerated without serious adverse events attributable to the product. » Więcej na de.investing.com


  • Armata submits phase‑3 protocol for AP‑SA02 against resistant staphylococci to FDA

    Armata has filed the complete phase‑3 protocol and responses to FDA feedback for the bacteriophage candidate AP‑SA02 to treat complicated S. aureus bacteremias. Four engineering runs have been completed in cGMP production in Los Angeles; production of clinical trial material and study start are planned for the second half of 2026. AP‑SA02 holds FDA designations Qualified Infectious Disease Product and Fast Track; the U.S. Department of Defense is funding development with an additional $2.5 million (total $28.7 million). Investors reacted positively, the share price rose markedly, and David House was promoted to CFO. » Więcej na de.investing.com


  • Armata receives fast-track status from FDA for phage drug AP-SA02

    The FDA has granted fast-track status to Armata’s intravenous multi-phage candidate AP-SA02 for the treatment of complicated S. aureus bacteremias, enabling more frequent interaction with the agency, rolling review of approval, and potentially accelerated approval. AP-SA02 showed positive Phase 1b/2a results, and Armata plans a Phase 3 superiority study in the second half of 2026. Analysts mostly rate the stock a buy with price targets of $15 to $20, although the company was recently unprofitable and reported a loss per share of $4.80. » Więcej na de.investing.com


  • Armata Pharmaceuticals schedules annual general meeting for June 11

    Armata Pharmaceuticals has scheduled its annual general meeting for June 11, 2026 at 8:30 a.m. Pacific Time at its headquarters in Los Angeles. Shareholders eligible to receive notice and vote are those recorded in the share register at the close of business on April 17, 2026; the deadline for shareholder proposals and director nominations is April 12, 2026 at 5:00 p.m. Pacific Time. The company also reported weak quarterly results: adjusted EPS of -$3.42 and revenue of $1.1 million, both well below expectations. » Więcej na de.investing.com


  • Armata Pharmaceuticals: stock falls after delay of quarterly report despite FDA status for AP-SA02

    Armata Pharmaceuticals delays publication of its Q4 and full-year 2025 report and expects to file the 10-K by no later than March 31, 2026, after which the stock dropped sharply. The FDA has granted the phage candidate AP-SA02 QIDP status, providing development incentives and the possibility of a five-year extension of market exclusivity; a Fast Track application has been submitted. The FDA considers the phase-2a data sufficient to start a phase-3 trial, planned to begin in the second half of 2026. In addition, the cGMP manufacturing facility in Los Angeles has been commissioned; market capitalization is around $310.91 million and an analysis suggests possible overvaluation. » Więcej na de.investing.com

Dane finansowe

W ostatnim kwartale Armata Pharmaceuticals osiągnęła przychody w wysokości 2,8 mln € i zysk netto w wysokości 48,43 mln €

(EUR) wrzesień 2026
YoY
Przychody 2,8 mln -
Zysk brutto 2,29 mln -
Zysk netto 48,43 mln 313,06%
EBITDA 55,61 mln 397,19%

Dane fundamentalne

Wskaźnik Wartość
Kapitalizacja rynkowa
107,45 mln €
Liczba akcji
37,19 mln
Maksimum/minimum z 52 tygodni
13,65 € - 2,19 €
Dywidendy Nie
Beta
1,41
C/Z (PE Ratio)
-0,93
PEG (PEG Ratio)
0,00
C/WK (PB Ratio)
0,00
C/S (PS Ratio)
18,22

Profil spółki

Armata Pharmaceuticals, Inc., spółka biotechnologiczna będąca w fazie badań klinicznych, koncentruje się na opracowywaniu ukierunkowanych terapii bakteriofagowych przeciwko zakażeniom opornym na antybiotyki na całym świecie. Firma tworzy swoje produkty przy użyciu własnej, zastrzeżonej technologii opartej na bakteriofagach. Kandydaci na produkty spółki obejmują AP-SA02 do leczenia bakteriemii wywoływanej przez Staphylococcus aureus; AP-PA02 przeciwko Pseudomonas aeruginosa; oraz AP-PA03 do leczenia zapalenia płuc. Spółka ma umowę o partnerstwie z Merck & Co. dotyczącą opracowywania syntetycznych kandydatów na bakteriofagi, które mają zwalczać nieujawnione czynniki chorób zakaźnych. Siedziba spółki znajduje się w Marina del Rey w Kalifornii.

Nazwa
Armata Pharmaceuticals
CEO
Deborah L. Birx
Siedziba Los Angeles, ca
Stany Zjednoczone
Strona internetowa
Sektor
Dobra podstawowe
Branża
Żywność
Debiut giełdowy
20.05.1994
Pracownicy 61

Symbole giełdowe

Giełda Symbol
AMEX
ARMP
Frankfurt
TG1N.F
München
TG1N.MU
Düsseldorf
TG1N.DU
🍪

Parqet  używa plików cookie. Dowiedz się więcej